<i>CXCR4</i><sup>S338X</sup> clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia.

导出 LinkOut

翻译打印收藏纠错

第一作者： Joshua N,Gustine

第一单位： Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.

作者： Joshua N,Gustine ^[1] ; Lian,Xu ^[2] ; Nicholas,Tsakmaklis ^[1] ; Maria G,Demos ^[1] ; Amanda,Kofides ^[1] ; Jiaji G,Chen ^[1] ; Xia,Liu ^[1] ; Manit,Munshi ^[1] ; Maria Luisa,Guerrera ^[1] ; Gloria G,Chan ^[1] ; Christopher J,Patterson ^[1] ; Andrew,Keezer ^[1] ; Kirsten,Meid ^[1] ; Toni,Dubeau ^[1] ; Guang,Yang ^[1] ; Zachary R,Hunter ^[1] ; Steven P,Treon ^[3] ; Jorge J,Castillo ^[1]

作者单位： Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA. ^[1] Department of Medicine, Boston University School of Medicine, Boston, MA; and. ^[2] Department of Medicine, Harvard Medical School, Boston, MA. ^[3]

关键词 CXCR4 Lymphomas and Other Lymphoproliferative Conditions MYD88 NEOPLASIA Waldenstr?m macroglobulinemia ibrutinib

主题词腺嘌呤(Adenine);抗药性(Drug Resistance);人类(Humans);突变(Mutation);髓样分化因子88(Myeloid Differentiation Factor 88);哌啶类(Piperidines);吡唑类(Pyrazoles);嘧啶类(Pyrimidines);受体, CXCR4(Receptors, CXCR4);治疗结果(Treatment Outcome);Waldenstrom巨球蛋白血症(Waldenstrom Macroglobulinemia)

DOI 10.1182/bloodadvances.2019000635

PMID 31570491

发布时间 2021-12-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Blood advances

2019年3卷19期

2800-2803页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

<i>CXCR4</i><sup>S338X</sup> clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia.

Blood advances

相似文献

Blood advances

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

<i>CXCR4</i><sup>S338X</sup> clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia.

Blood advances

相似文献

Blood advances

相关期刊

检索历史清除